loader image
Mustard Powder
Mustard powder is used in neuritis, neuralgias, sciatica, bronchitis, severe hypothermia, for the prevention of colds, hypertension, rheumatism. In chronic rhinitis, colds, flu, folk healers recommend to pour mustard powder into the socks and move like that a few days.

Mustard powder and health benefits

When applied topically irritating mustard powder`s action is widely used in the form of hot baths as a means of distraction, causing redistribution of blood (for example, bronchitis and pneumonia), and then person must be covered with a blanket.

Similarly, mustard powder is used for the local baths (foot). In this case, the bath temperature should be 39-40° C. Duration of treatment: 10 minutes. Mustard baths improve blood circulation, eases breathing, promote expectoration. The maximum duration of taking baths -10 days.

Mustard compress (1 tsp. of powder in a glass of warm water) used in pediatric practice in addition to mustard compress for colds. Compress is applied on the 1-10 minutes.

Mustard powder mixed with honey, and mixed on a white lily flowers decoction is used externally for freckles.

To improve the stomach`s work it is recommended to chew mustard powder. A weak solution of mustard powder, ingested, acting laxative and is used for constipation.

Mustard powder is used in phytocosmetics: oily hair can be washed with mustard 1 tbsp. of mustard powder is poured by 400 ml of warm water, thoroughly mixed, the mixture is applied to the hair and skin lightly rubbed and rinsed after 2-3 minutes.

For baldness: mustard powder thoroughly stirred into warm (not above 60° C) water and the resulting slurry should be lubricated baldness parts until intense burning. Then wash off the mustard. The procedure is repeated daily. If within a month the hair will not grow, the further use of mustard is not advisable.

To eliminate pigmentation: mustard powder is poured with water, stir until the consistency of pulp and lubricate pigmented skin. After the appearance of intense burning, mustard is washed and the skin is wiped dry. The procedure is carried out in a day. Course – 10 sessions.

Contraindications: dilated blood skin vessels and facial hirsutism in women. Preparations of mustard contraindicated in inflammation of the kidneys and pulmonary tuberculosis.

Mustard powder is used as an excellent cleaner for washing and cleaning dishes and removing greasy stains when washing wool and silk.

Because mustard perfectly emulsifies fats, greasy dishes are washed by it.

Mustard powder has been successfully used in home canning. Besides antiseptic action it gives the product a specific taste, flavor and smell.

Mustard powder – is a great natural preservative and antiseptic, it is used: – to prepare the mustard – for filling sauces, soups, hash – to increase the shelf life of preservation.

Mustard powder is also used as an insecticide: it effectively influences the leaf-eating insects. This is – an eco-clean product for pest control in the garden because it has strong antibacterial properties and influences disinfecting on agents of some plant diseases.

Mustard powder is used in neuritis, neuralgia, sciatica, bronchitis, severe hypothermia, for the prevention of colds, hypertension, rheumatism. In chronic rhinitis, colds, flu, healers recommend to pour mustard powder in stockings or socks and go like that a few days.

MAKE A STEP TOWADS TO

LONGEVITY!

GET IN TOUCH WITH US

    3+6=

     

    Global Longevity Disclaimer

    Potentially interested parties should note that participation in the Global Longevity project is subject to limitations imposed by applicable securities laws in various jurisdictions.

    Potential investors should note that participation in the Global Longevity Sale is subject to limitations imposed by applicable securities laws in various jurisdictions. The following does neither constitute an offer to buy or to subscribe for the Potentially interested parties should note that participation in the Global Longevity project is subject to limitations imposed by applicable securities laws in various jurisdictions.

    Potential investors should note that participation in the Global Longevity project Sale is subject to limitations imposed by applicable securities laws in various jurisdictions. The following does neither constitute an offer to buy or to subscribe for the Global Longevity project. Investors should make their decision to buy or to subscribe to Global Longevity project.

    Investors are furthermore advised to consult their bank or financial adviser before making any investment decision. This publication may contain specific forward-looking statements, e.g. statements including terms like “believe”, assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements.

    Against the background of these uncertainties, readers should not rely on forward-looking statements. Global Longevity project assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.

    The Global Longevity project are not for sale and distribution, directly or indirectly, in or into the United States (including its territories and dependencies, any state of the United States and the District of Columbia), Canada, Japan, Australia, North Korea, Iran, Myanmar, Afghanistan, Angola, Aruba, Bangladesh, Belarus, Benin, Bhutan, Bolivia, Botswana, Brunei Darussalam, Burkina Faso, Bosnia, Burundi, Cambodia, Cameroon, Cape Verde, Central Africa republic, Chad, Comorros, Congo, Congo Democratic republic, Cuba, Cote d’Ivoire, Djibouti, Dominica, Ecuador, El Salvador, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guatemala, Guyana, Guinea, Guinea Bissau, Haiti, Honduras, Iraq, Jordan, Kenya, Kyrgyz Republic, Laos People’s Republic, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Micronesia, Moldova, Mongolia, Mozambique, Nauru, Nepal, New Caledonia, Nicaragua, Niger, Nigeria, Niue, Oman, Pakistan, Palestinian Areas, Papua New Guinea, Reunion, Rwanda, Samoa, Sao Tome and Principe, Senegal, Sierra Leone, Somalia, South Georgia, Sudan, Sri Lanka, Suriname, Syria, Swaziland, Tajikistan, Tanzania, Timor, Togo, Tonga, Tunisia, Turkmenistan, Uganda, Uzbekistan, Venezuela, Western Sahara, Yemen, Zambia, Zimbabwe or any jurisdiction into which the same would be unlawful.

    This announcement does not constitute or form a part of any offer or solicitation to purchase, subscribe for or otherwise acquire securities in the United States, Canada, Japan, Australia, North Korea, Iran, Myanmar,Afghanistan, Angola, Aruba, Bangladesh, Belarus, Benin, Bhutan, Bolivia, Botswana, Brunei Darussalam, Burkina Faso, Bosnia, Burundi, Cambodia, Cameroon, Cape Verde,Central Africa republic, Chad, Comorros, Congo, Congo Democratic republic, Cuba, Cote d’Ivoire, Djibouti, Dominica, Ecuador, El Salvador, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guatemala, Guyana, Guinea, Guinea Bissau, Haiti, Honduras, Iraq, Jordan, Kenya, Kyrgyz Republic, Laos People’s Republic, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Micronesia, Moldova, Mongolia, Mozambique, Nauru, Nepal, New Caledonia, Nicaragua, Niger, Nigeria, Niue, Oman, Pakistan, Palestinian Areas, Papua New Guinea, Reunion, Rwanda, Samoa, Sao Tome and Principe, Senegal, Sierra Leone, Somalia, South Georgia, Sudan, Sri Lanka, Suriname, Syria, Swaziland, Tajikistan, Tanzania, Timor, Togo, Tonga, Tunisia, Turkmenistan, Uganda, Uzbekistan, Venezuela, Western Sahara, Yemen, Zambia, Zimbabwe or any jurisdiction in which such an offer or solicitation is unlawful.

    The Global Longevity project will not be registered under the US Securities Act of 1933, as amended or under any securities laws of any state or other jurisdiction of the United States and may not be offered, sold, taken up, exercised, resold, renounced, transferred or delivered, directly or indirectly, within the United States.

    The Global Longevity project have not been approved or disapproved by the US Securities and Exchange Commission, any state’s securities commission in the United States or any US regulatory authority, nor have any of the foregoing authorities passed upon or endorsed the merits of the offering of the Global Longevity project or the accuracy or adequacy of this announcement. Any representation to the contrary is a criminal offence in the United States. The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom.

    This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The Global Longevity project are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such the Global Longevity project will be engaged in only with, relevant persons.

    Any person who is not a relevant person should not act or rely on this document or any of its contents. Any offer of securities to the public that may be deemed to be made pursuant to this communication in any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”) is only addressed to qualified investors in that Member State within the meaning of the Prospectus Directive.